Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome
|
|
- Jared Atkinson
- 5 years ago
- Views:
Transcription
1 Page 1 of 17 Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome MANUAL OF OPERATIONS VERSION 5.0 August 1, 2017
2 Page 2 of 17 STUDY PERSONNEL CONTACT INFORMATION Principal Investigator: Lead Study Coordinator: NAPRTCS Contact: Mark Benfield, MD Pediatric Nephrology of Alabama, P.C Richard Arrington Jr. Blvd. South Suite 206 Birmingham, Alabama Phone: Fax: benfield@pednephal.com Michelle Benfield RN, BSN, CCRC Pediatric Nephrology of Alabama, P.C Richard Arrington Jr. Blvd. South Suite 206 Birmingham, Alabama Phone: Fax: embenfield@pednephal.com Danielle Lang Executive Director NAPRTCS 1 Autumn St. Box 729 Boston, MA Phone: Fax: lang@naprtcs.org DCC Director: DCC Senior Statistician And Database Manager: Traci Leong, PhD Medalytics Phone: medalyticsgroup@gmail.com Courtney McCracken, PhD Medalytics Phone: medalyticsgroup@gmail.com
3 Page 3 of 17 SCIENTIFIC ADVISORY COMMITTEE MEMBERS: Mark Benfield, MD Pediatric Nephrology of Alabama, P.C Richard Arrington Jr. Blvd. South Suite 206 Birmingham, Alabama Phone: Fax: Larry Greenbaum, MD Marcus Professor of Pediatrics Division of Pediatric Nephrology Emory University School of Medicine 2015 Uppergate Dr. NE Atlanta, Georgia, Phone: Fax: Paul Grimm, MD Professor of Pediatrics Medical Director, Pediatric Kidney Transplant Program Stanford University School of Medicine G306, MC Pasteur Drive Stanford, CA Phone: Fax: Kenneth Lieberman, MD Chief, Pediatric Nephrology Joseph M. Sanzari Children s Hospital Hackensack University Medical Center Professor of Pediatrics Rutgers New Jersey Medical School Phone: Fax:
4 Page 4 of 17 ROLES AND RESPONSIBILITIES Principal Investigator: The PI will be responsible for development of processes, forms, and conduct of study; site recruitment; development and management of scientific advisory committee, working with Medalytics for data analysis and preparation of publications. Lead Study Coordinator: The study coordinator will be responsible for developing regulatory documents and compliance, working with each of the sites during site recruitment, site initiation, patient recruitment, enrollment and data entry. Their role will be assure clear and effective communication, assist with queries during study development, initiation, and conduct. Data Coordinating Center: Medalytics will be the data coordinating center. They will be responsible for developing data entry forms; training sites to use web-based data entry system; data entry and integrity; data analysis. Interim analyses will be conducted yearly but analyses for the primary publication will be conducted at the end of the study. Participating centers can submit requests for special studies and analysis to further investigate and report on data in the registry. These analyses will be approved by the scientific advisory committee and all analyses performed with the assistance of Medalytics. NAPRTCS: NAPRTCS will be the study coordinating center. They will be responsible for coordinating site initiating and assuring appropriate contracting and IRB regulatory documents have been completed. All contracts with sites and data coordinating center will be as a subcontract of NAPRTCS. Scientific Advisory Committee: The role of the scientific advisory committee is to develop data forms and update as needed, disseminate information regarding registry and recruitment, work with data coordinating center to develop first data analysis at 1 year and be authors on initial manuscript(s).
5 Page 5 of 17 ABBREVIATIONS AE CRF DCC FSGS GFR IRB ADVERSE EVENT CASE REPORT FORM DATA COORDINATING CENTER FOCAL SEGMENTAL GLOMERULAR SCLEROSIS GLOMERULAR FULTRATION RATE INSTITUTIONAL REVIEW BOARD MCNS MINIMAL CHANGE DISEASE MPGN MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS NS SAE SDNS SLE SSNS SRNS UP/C NEPHROTIC SYNDROME SERIOUS ADVERSE EVENT STEROID DEPENDENT NEPHROTIC SYNDROME SYSTEMIC LUPUS ERYTHEMATOSUS STEROID SENSITIVE NEPHROTIC SYNDROME STEROID RESISTANT NEPHROTIC SYNDROME URINE PROTEIN CREATININE RATIO DEFINITIONS 1. Nephrotic Syndrome (Diagnosis requires all 3) a. Proteinuria urine protein/creatinine ratio > 3 or 24 Hr urine > 3000 mg b. Hypoalbuminemia Serum albumin less than 2.5 c. Edema clinical diagnosis 2. RESPONSE TO THERAPY (steroid, ACTHar, or any other treatment) a. Therapy Responsive NS (Diagnosis requires all 3 when available. Labs that are not done do not effect definition. However parameters checked but outside of range should be evaluated as below. E.g. if albumin not done it could be steroid responsive. If albumin done and <3.5 it would be a partial response)
6 Page 6 of 17 i. Proteinuria Urine protein/creatinine ratio decrease to < 0.5 or dipstick less than 1+ for 3 consecutive days ii. Hypoalbuminemia serum albumin increased to > 3.5 iii. Edema no clinical edema b. Partially Responsive NS (Diagnosis requires any 1 of 3) i. Proteinuria Urine protein/creatinine ratio decreased by > 50% ii. Hypoalbuminemia serum albumin increase by > 0.5 iii. Edema no clinical edema 3. Steroid dependent NS a. Relapse during steroid taper or within 2 weeks of stopping steroids. 4. Steroid resistant NS/Non-responsive NS a. Unresponsive to 4 weeks of high dose steroid or other therapy 5. Relapse in patient with complete response (Diagnosis requires any 1 of 3 usually only #1) a. Proteinuria 2-4+ dipstick proteinuria for 3 consecutive days (This can be home, office, or hospital monitoring), Pro/Cr > 3 b. Hypoalbuminemia - Serum albumin less than 2.5 c. Edema clinical diagnosis 6. Relapse in patient with partial response (Diagnosis requires any 1 of 3) a. Proteinuria worsening of urine protein/creatinine ratio b. Hypoalbuminemia - Serum albumin decreased by 0.5 c. Edema clinical diagnosis 7. Infrequently relapsing NS a. 3 or fewer relapses per year 8. Frequently relapsing NS a. 4 or more relapses per year b. 2 or more relapses in a 6 month period 9. Oral Steroid Course a. High Dose daily divided steroids for induction of remission (not dependent on subsequent response)
7 Page 7 of 17 REGULATORY REQUIREMENTS Centers participating in this registry must follow applicable regulatory and institutional requirements and Good Clinical Practice (GCP) guidelines. Documentation of participant consent and source documentation for all data must be on file at the participating site. Sites are responsible for ensuring that all data submitted are collected from source documents and entered accurately into the system. PATIENT POPULATION The potential subject must have received his/her first dose of ACTHar 6 months to 21 years of age. The age criteria is reflective of the first dose of ACTHar which is the data collection starting point. Turning 21 years of age during data collection is not a stopping point. The site can continue to collect data every 6 months as long as the local IRB approves the process and HIPAA guidelines are followed. It is not always logistically possible to follow patients once they have transitioned to adult care so data collection past transition is up to each site. Children 6 months to 21 years of age, with nephrotic syndrome of any cause, and treated with ACTHar therapy (patients who have received one dose of ACTHar will be able to be included in the registry) will be eligible for enrollment (including but not limited to idiopathic NS, FSGS, MPGN, IgA Nephropathy, Membranous Nephropathy, SLE). Nephrotic syndrome is very rare in children less than 1 year of age and treatment failures of traditional therapies often encompass several years. However it is important to capture all children treated with ACTHar and if local clinical decisions lead to the use of this therapy in infancy, it would be important to collect and analyze these data. The NIH and FDA define pediatrics as up to the 21st birthday. We will make every effort to transition all young adult patients to the adult registry of ACTHar use when they transition their care from pediatric nephrology to adult based care. This represents a very small number of patients and it is difficult to accurately estimate the number that will be treated with ACTHar. However it is likely that patients per year will be enrolled. There will be 25 sites for this registry. Although goal enrollment for each site is 2, we hope all sites are able to enroll all patients who have been treated with ACTHar. STUDY DESIGN This study will be an observational study utilizing a data registry of practice patterns and clinical outcomes in children with NS treated with ACTHar. We will utilize the infrastructure, clinical trial network, and experience of the North American Pediatric Trials and Collaborative Studies (NAPRTCS) and the data coordinating center Medalytics. NAPRTCS was founded in 1987 initially as a data registry for pediatric kidney transplantation. However it is now a 501 c 3 organization studying outcomes in children with CKD, Dialysis and Transplantation. This organization now includes 120 centers in the United States, Canada and Mexico. For the purposes of this study we would only utilize US centers. Utilizing this network will allow for efficient development and implementation of the data registry of ACTHar use, access to a large number of centers with a long track
8 Page 8 of 17 record of involvement with data registries, an existing web-based data entry system, and the guidance, oversight, data acquisition and analysis of an established data coordinating center. This study will have very limited traditional inclusion and exclusion criteria. This will not be a treatment study and inclusion/exclusion criteria do not pertain to decisions to use ACTHar. Our goal will be to capture as many patients as possible who have been treated with ACTHar for Nephrotic Syndrome. We propose to collect data from both incident and prevalent patients treated with ACTHar (this can be either retrospective or prospective), at the time of first ACTHar use, 1 month following initiating of therapy, follow-up forms every 6 months, and with any relapse of NS. The registry is funded for 5 years (year 1 was 2015). Each subject enrolled during the funded years will have data collected up to 5 years, depending on the timepoint of their enrollment (first dose of ACTHar). An extension will be requested by the coordinating center and sites will be notified during year 4 of the status. FORMS SCHEDULE ENROLLMENT 1 MONTH (+/-7d) *EVERY 6 MONTHS AS INDICATED Enrollment Form X Status/follow up form X X SAE Form X AE Form X Con Med Form X X X X (update form as needed) Relapse (update X form as needed) Dosing Form X X X X Termination Form X Data entry should be completed within 30 days of study visit. *Use the clinic visit that is closest to the 6 month target date. ENROLLMENT Enrollment Form Informed Consent will be performed prior to collection of any data. Labs recorded for enrollment form should be pre ACTHar dose. This is a registry that reflects practice patterns of sites. Therefore labs collected will be those of each sites standard of care. Nephrotic Syndrome Classification (See Definitions) o Steroid Responsive-Infrequently relapsing o Steroid Responsive-Frequently relapsing o Steroid Dependent o Partially Responsive
9 Page 9 of 17 o Steroid Resistant/Nonresponsive If patient has had more than one transplant, please use date of most recent transplant. Upload all previous kidney biopsy reports (prior to treatment of ACTHar) If patient has diagnosis of hypertension, please report number of medications used to treat hypertension. This should not include those medications used solely for purpose of anti-proteinuric affect. ACTHar timing and dosing Information o Capture if initial dose was the target dose or if the subject is on a planned dose escalation schedule in order to reach target dose. Below is an example of a subject who started at a dose of 48 units once a week but the planned target was 48 units 3 times a week. There will be a separate training manual available to provide guidance for data entry.
10 Page 10 of 17 Previous Used IV Therapies and Oral Therapies for Nephrotic Syndrome o Enter the number of courses since diagnosis (from date of diagnosis to the date of the first dose ACTHar) and the maximum dose prescribed for this subject. o If a subject is on a therapy for NS at the initiation of ACTHar therapy, include that course in the number entered in Previous used therapies and also enter that course in the most recent therapy section. Most Recent Therapy for Nephrotic Syndrome o Enter the most recent course prior to start of ACTHar. If a subject is on a therapy for NS at the initiation of ACTHar therapy, that current therapy would be the most recent course. o Oral prednisone use is captured under the relapse history section Below are examples from a subject who had one course of solumedrol prior to first dose of ACTHar and one course of mycophenolate mofetil prior to first dose of ACTHar. These were also his/her most recent courses of these therapies.
11 Page 11 of 17 Concomitant Medications-Conmeds to be collected will be immunosuppressant medications, antihypertensive medications (including those used for antiproteinuric affect), lipid lowering agents, diuretics and albumin. o Oral Prednisone exposure is captured under Medication changes section and should not be captured on Conmed form. o Upload ConMed form This is a word document that can be updated at each visit. Please enter a new line for each dose change. Below is an example of a subject who had multiple changes in Lisinopril dose.
12 Page 12 of 17 ACTHar Dosing Form o Capture initial ACTHar dose. Labs collected at the initial ACTHar dose will be captured on the enrollment form. o Add an ACTHar dose change form for each dose change o Labs will be requested at each dose change. These labs will include urine protein, urine protein/creatinine ratio, serum albumin and serum creatinine.
13 Page 13 of 17 1 MONTH VISIT FROM TIME OF INITIATION OF ACTHAR (+/- 7 day window) Status Form (Follow Up form) Hospitalization since last visit o Complete SAE form Biopsy since last visit o Biopsy report will be uploaded Relapse since last visit o Update relapse form. Albumin, serum creatinine, proteinuria and protein/creatinine ratio are captured with each relapse if available. These labs are those that indicated a relapse, therefore should reflect the date of relapse or prior to this date. Please do not enter labs that were collected after treatment for relapse was started. o See definitions for response to treatment Infection since last visit o Complete AE/SAE form SAE since last visit o Complete SAE form
14 Page 14 of 17 AE (those associated with ACTHar use only) o Complete AE/SAE form Concomitant Medications-Conmeds to be collected will be immunosuppressant medications, antihypertensive medications (including those used for antiproteinuric affect), lipid lowering agents, diuretics and albumin. o Oral Prednisone exposure is captured under Medication changes section and should not be captured on Conmed form. o Upload ConMed form o This is a word document that can be updated at each visit. Please enter a new line for each dose change. Lab work o This is a registry that reflects practice patterns of sites. Therefore labs collected will be those of each sites standard of care. ACTHar Dosing Form o Capture ACTHar dose changes and labs associated with these changes (serum albumin, urine protein, urine protein creatinine ratio, serum creatinine). Some dose changes are planned while others are due to clinical status. Therefore the labs captured for Acthar dose change should be those labs collected on the day of dose change or prior to the dose change. AE Form o Those associated with ACTHar use only o Adrenal insufficiency-based on PI s judgment FOLLOW UP VISITS OCCURS EVERY 6 MONTHS FROM TIME OF INITIATION OF ACTHAR. Use the clinic date that is closest to the 6 month target date. Status Form (Follow Up form) Hospitalization since last visit o Complete SAE form Biopsy since last visit o Biopsy report will be uploaded Relapse since last visit o Update relapse form o See definitions for response to treatment Infection since last visit o Complete AE/SAE form SAE since last visit o Complete SAE form AE o o Those associated with ACTHar use only Complete AE/SAE form
15 Page 15 of 17 ADVERSE EVENTS Concomitant Medications-Conmeds to be collected will be immunosuppressant medications, antihypertensive medications (including those used for antiproteinuric affect), lipid lowering agents, diuretics and albumin. o Oral Prednisone exposure is captured under Medication changes section and should not be captured on Conmed form. o Upload ConMed form o This is a word document that can be updated at each visit. Please enter a new line for each dose change. Lab work o This is a registry that reflects practice patterns of sites. Therefore labs collected will be those of each sites standard of care. ACTHar Dosing Form o Capture ACTHar dose changes and labs associated with these changes (serum albumin, urine protein, urine protein creatinine ratio, serum creatinine). Some dose changes are planned while others are due to clinical status. Therefore the labs captured for Acthar dose change should be those labs collected on the day of dose change or prior to the dose change. AE Form o Adrenal insufficiency-based on PI s judgment Only adverse events associated with Nephrotic syndrome and/or ACTHar use will be reported. These will include the following: Infection (bacterial, fungal, or viral) that requires treatment with an antibiotic (systemic or topical) New behavioral changes that are interfering with school or home functioning New sleep disturbances that are viewed as significant by the parent/child Increase in blood pressure that requires a new antihypertensive medication or an increase in dose of an antihypertensive medication that the patient is already receiving Generalized increase in skin pigmentation ( bronzing ) Increase in Cushingoid symptoms such as moon facies or striae Increase in serum glucose >200mg/dL on a random sample Adrenal insufficiency-(reported based on PI s discretion) Pain, redness or swelling at ACTHar injection site AE s (Only adverse events associated with Nephrotic syndrome and/or ACTHar use will be reported) and SAE s will be collected for the entire time the subject is enrolled in the registry.
16 Page 16 of 17 SERIOUS ADVERSE EVENTS All SAE s will be reported but since this is not a drug study, it is not required that these are reported within 24 hours of the site becoming aware of the event. It is required that SAEs are reported at each of the follow up visits. Results in Death Life-threatening Hospitalization (initial or prolonged) Results in Persistent or Significant Disability or Permanent Damage Congenital Anomaly/Birth Defect Other Serious (Important Medical Events)-Report when the event does not fit the other outcomes, but the event may jeopardize the patient and may require medical or surgical intervention (treatment) to prevent one of the other outcomes. AE s (Only adverse events associated with Nephrotic syndrome and/or ACTHar use will be reported) and SAE s will be collected for the entire time the subject is enrolled in the registry. REASON FOR TERMINATION Subject requires Dialysis Subject Receives a Kidney transplant Subject Request to withdraw consent MEDICATIONS Concomitant Medications-Conmeds to be collected will be immunosuppressant medications, antihypertensive medications (including those used for anti-proteinuric affect), lipid lowering agents, diuretics and albumin. All medications will be listed by generic/common names and not by trade or brand names. The concomitant medication form is a word document. Enter a new line for all dose changes. PATIENT IDENTIFIER Patient will be identified by the site s NAPRTCS site number and then sequentially by enrollment. X X X NAPRTCS Site #/Enrollment#
17 Page 17 of 17 APPENDIX A Clarification of Classifications There are 3 levels of classification 1. Diagnosis 2. Response to steroids 3. Response to any therapy a. Remission b. Relpase 1. Diagnosis a. This is a clinical and/or biopsy diagnosis at the beginning of the disease process and includes: i. Minimal Change ii. FSGS iii. IgA iv. MPGN v. Membranous vi. SLE vii. Other b. This should not include diagnosis/classification related to response to steroids or any other therapy 2. Response to steroids a. The primary treatment is fairly uniformly going to be steroids so the initial response to therapy classification has to do with response to steroids and relapses related to steroid therpy i. Steroid responsive infrequently relapsing ii. Steroid responsive frequently relapsing iii. Steroid dependent iv. Steroid resistant 3. Relapse and Remission a. The definition of each of these is outlined in the MOP b. They are independent of therapy used.
Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome
Page 1 of 16 Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome MANUAL OF OPERATIONS VERSION 1.0 March 10, 2016 Page 2 of 16 STUDY PERSONNEL CONTACT INFORMATION Principal
More informationNephrotic Syndrome NS
Nephrotic Syndrome NS By : Dr. Iman.M. Mudawi Pediatric Nephrology Unit Gaafar Ibn Auf Hospital Definitions: In children NS is applied to any condition with a triad of: Heavy proteinuria (UACR ratio >200
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationActhar Gel. H. P. Acthar Gel (corticotropin; ACTH) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.10 Subject: Acthar Gel Page: 1 of 7 Last Review Date: November 30, 2018 Acthar Gel Description H.
More informationNephrotic Syndrome. Sara Alsharhan PharmD candidate, KSU 2014
Nephrotic Syndrome Sara Alsharhan PharmD candidate, KSU 2014 Outline Introduction Nephrotic syndrome classifications Signs and symptoms Diagnoses Management Complications Monitoring Case presentation Introduction
More informationActhar Gel. H. P. Acthar Gel (corticotropin; ACTH) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.10 Subject: Acthar Gel Page: 1 of 6 Last Review Date: December 8, 2017 Acthar Gel Description H. P.
More informationNephrotic syndrome in children. Bashir Admani KPA Nephrology Precongress 24/4/2018
Nephrotic syndrome in children Bashir Admani KPA Nephrology Precongress 24/4/2018 What is Nephrotic syndrome?? Nephrotic syndrome is caused by renal diseases that increase the permeability across the glomerular
More informationNephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba
Nephrotic syndrome minimal change disease vs. IgA nephropathy Hadar Meringer Internal medicine B Sheba The Case 29 year old man diagnosed with nephrotic syndrome 2 weeks ago and complaining now about Lt.flank
More informationUse of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome
Pediatr Nephrol (2003) 18:833 837 DOI 10.1007/s00467-003-1175-4 BRIEF REPORT Gina-Marie Barletta William E. Smoyer Timothy E. Bunchman Joseph T. Flynn David B. Kershaw Use of mycophenolate mofetil in steroid-dependent
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationLONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE
& LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE Senija Rašić 1 *, Amira Srna 1, Snežana Unčanin 1, Jasminka Džemidžić 1, Damir Rebić 1, Alma Muslimović 1, Maida Rakanović-Todić
More informationUrinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease
KIDNEY DISEASES Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease Heba Mostafa Ahmed, 1 Dina Ahmed Ezzat, 1 Noha A Doudar, 2 Mai Adel 1 1 Departement of Pediatrics,
More informationClots and Foamy Urine: Thrombotic Complications of Nephrotic Syndrome. Prayus Tailor, MD October 5, 2013 Renal and Hypertension Symposium
Clots and Foamy Urine: Thrombotic Complications of Nephrotic Syndrome Prayus Tailor, MD October 5, 2013 Renal and Hypertension Symposium Objectives Discuss the pathophysiology of thrombosis in nephrotic
More informationFebruary 20, 2019 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES
February 20, 209 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES Forward-Looking Statements This presentation contains certain forward-looking statements that are made pursuant
More informationINFORMATION TO HELP GUIDE YOUR TREATMENT
INFORMATION TO HELP GUIDE YOUR TREATMENT H.P. Acthar Gel (repository corticotropin injection) is indicated for the reduction of proteinuria in people with nephrotic syndrome of the idiopathic type (unknown
More informationThe Value Of Tacrolimus Drug Levels In The Management Of Nephrotic Syndrome In Children
ISPUB.COM The Internet Journal of Nephrology Volume 6 Number 2 The Value Of Tacrolimus Drug Levels In The Management Of Nephrotic Syndrome In Children K Peyser, Y Steinberg, R Frank, S Vento, L Infante,
More informationSteroid Resistant Nephrotic Syndrome. Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta
Steroid Resistant Nephrotic Syndrome Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta From the Departments of Nephrology, Pathology* and Biostatistics**,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationGlomerular Pathology- 1 Nephrotic Syndrome. Dr. Nisreen Abu Shahin
Glomerular Pathology- 1 Nephrotic Syndrome Dr. Nisreen Abu Shahin The Nephrotic Syndrome a clinical complex resulting from glomerular disease & includes the following: (1) massive proteinuria (3.5 gm /day
More information3. Screening Subject Identification Screening Overview
3. Screening 3.1 Subject Identification Each site will be responsible for identifying and recruiting participants into the study. It is known that screening methods vary across sites. It is, however, important
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationDisorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.
Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome. Azotemia and Urinary Abnormalities Disturbances in urine volume oliguria, anuria, polyuria Abnormalities of urine sediment red
More informationMinimizing Growth Suppression in Children with Steroid-sensitive Nephrotic Syndrome
Minimizing Growth Suppression in Children with Steroid-sensitive Nephrotic Syndrome Alex Constantinescu, MD Director, Pediatric Nephrology Joe DiMaggio Children s Hospital Hollywood, Florida Outline Define
More informationAurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis
August 15, 2016 Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis Conference call and webcast at 8am ET First therapeutic agent to meet
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationEffect of Levamisole in Steroid-Dependent Nephrotic Syndrome
Kidney Diseases Effect of Levamisole in Steroid-Dependent Nephrotic Syndrome Abbas Madani, 1 Seyed-Taher Isfahani, 1 Nahid Rahimzadeh, 2 Seyed-Mohammad Fereshtehnejad, 3 Rozita Hoseini, 4 Mastaneh Moghtaderi,
More informationEditorial. Recent Concepts in Management of Nephrotic Syndrome
Editorial Recent Concepts in Management of Nephrotic Syndrome This is the third editorial on nephrotic syndrome in this journal in last 4 years. The previous 2 editorials were addressed to problems of
More informationTypes Pathophysiology Clinical manifestations D.Dx. Investigations. Treatment. Complications.
Types Pathophysiology Clinical manifestations D.Dx. Investigations. Treatment. Complications. Nephrotic syndrome affects 1-3 per 100,000 children
More informationManagement and Outcome of Steroid-Resistant Nephrotic Syndrome in Children
kidney diseases Management and Outcome of Steroid-Resistant Nephrotic Syndrome in Children Hasan Otukesh, 1 Salman Otukesh, 2 Mona Mojtahedzadeh, 2 Rozita Hoseini, 1 Seyed-Mohammad Fereshtehnejad, 2 Azam
More informationElevated Serum Creatinine, a simplified approach
Elevated Serum Creatinine, a simplified approach Primary Care Update Creighton University School of Medicine. April 27 th, 2018 Disclosure Slide I have no disclosures and have no conflicts with this presentation.
More informationNephrotic syndrome Dr.Basma Adel FIFTH GRADE
Nephrotic syndrome Dr.Basma Adel FIFTH GRADE 2017-2018 At the end of this lecture you should know: Types Pathophysiology Clinical manifestations D.Dx. Investigations. Treatment. Complications. 12/3/2017
More informationProteinuria Nephrotic syndrome
Proteinuria Nephrotic syndrome Pathophysiology & management Miriam Davidovits, MD Institute of Nephrology Schneider Children s Medical Center of Israel 1 Abnormal excretion of protein into the urine is
More informationGOOD MORNING. Welcome Applicants! Friday, October 31, (Happy Halloween!)
GOOD MORNING Welcome Applicants! Friday, October 31, 2014 (Happy Halloween!) PREP QUESTION A 14-year-old girl has had 3 days of new, unremitting headache associated with vomiting and awakening from sleep
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home > Inspections, Compliance, Enforcement, and Criminal Investigations > Enforcement Actions > Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Punjwani, Sohail S., M.D.
More informationPaediatrics Dr. Bakr Lecture 3 Nephrotic Syndrome
P a g e 1 DEFINITION Paediatrics Dr. Bakr Lecture 3 Nephrotic Syndrome Definition: nephrotic syndrome is a disorder characterized by heavy proteinuria with hypoprpteinimia,hyper lipidemia and edema. It
More informationUpdates on Paediatric clinical research activities
Updates on Paediatric clinical research activities Shivaram Hegde Consultant paediatric nephrologist Children Kidney centre UHW, Cardiff Aim to Brief introduction Research updates Improve contribution
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationIdiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses
Nephrol Dial Transplant (2003) 18: 1316 1320 DOI: 10.1093/ndt/gfg134 Original Article Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses Kai-Chung
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationResistant Nephrotic Syndrome: Review of Trials Using ACTH and a Case Series of Six Patients Treated with ACTHar
British Journal of Medicine & Medical Research 5(11): 1453-1457, 2015, Article no.bjmmr.2015.164 ISSN: 2231-0614 SCIENCEDOMAIN international www.sciencedomain.org Resistant Nephrotic Syndrome: Review of
More informationWELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Adverse Events in Clinical Trials: Definitions and Documentation May 2016 Objectives Recognize the
More informationProteinuria Nephrotic syndrome
Proteinuria Nephrotic syndrome Pathophysiology & management Miriam Davidovits, MD Institute of Nephrology Schneider Children s Medical Center of Israel 1 Abnormal excretion of protein into the urine is
More informationKDIGO GN Guideline update Evidence summary. Steroid-sensitive nephrotic syndrome. Corticosteroid therapy for nephrotic syndrome in children
KDIGO GN Guideline update Evidence summary Steroid-sensitive nephrotic syndrome Corticosteroid therapy for nephrotic syndrome in children PICO question In children (aged 3 to 18 years of age) with steroid-sensitive
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2006 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationBaseline Patient Forms
Revision of 06/14/2016 Page 1 of 7 CKD PILOT STUDIES Forms Completion Schedule - COMBINE Non-Patient Forms In order to make a clinical site ready to enroll F09 Clinical Center F10 Study Personnel Review
More informationPrimary Nephrotic Syndrome. Mao Jianhua, Department of Nephrology, The Children s Hospital of Zhejiang University School of Medicine
Primary Nephrotic Syndrome Mao Jianhua, Department of Nephrology, The Children s Hospital of Zhejiang University School of Medicine Introduction Nephrotic syndrome is a group of symptoms including proteins
More informationDra. Irma Esther del Moral Espinosa Nefrología Pediátrica Hospital Infantil de México Federico Gómez
Dra. Irma Esther del Moral Espinosa Nefrología Pediátrica Hospital Infantil de México Federico Gómez drairma.nefroped@gmail.com Many children with idiopathic nephrotic syndrome initially respond to steroid
More informationNorth American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency
North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationEpidemiology of CKD in Children
Epidemiology of CKD in Children Ali Düzova, M.D. Hacettepe University Faculty of Medicine Pediatric Nephrology and Rheumatology Unit Ankara CKD Course 03 June 2011, İstanbul Aim & Plan Causes of CKD in
More informationChapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org chapter 6 & 2012 KDIGO Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, 181 185; doi:10.1038/kisup.2012.19
More informationProfessor Suetonia Palmer
Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS
More informationNEPHROTIC SYNDROME SYMPOSIUM
NEPHROTIC SYNDROME SYMPOSIUM NOVEMBER 4, 2016 8:30 AM - 3:40 PM The New York Academy of Medicine 1216 Fifth Avenue New York, NY 10029 COURSE DIRECTORS Gerald B. Appel, MD Columbia University College of
More informationManagement of Nephrotic Syndrome
Management of Nephrotic Syndrome 1. Introduction Incidence 2-4/100,000. Boys > girls 3:2; age of onset 2-6 years 80% of cases in children is due to minimal change (MCD) of which 80% will respond to steroid
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 28 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationRITAZAREM. CRF Completion Guidelines
RITAZAREM CRF Completion Trial Title: Protocol Number: An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated
More informationDeflazacort Versus Prednisolone: Randomized Controlled Trial in Treatment of Children With Idiopathic Nephrotic Syndrome
Iran J Pediatr. 2015 April; 25(2):e510. Published online 2015 April 18. DOI: 10.5812/ijp.510 Research Article Deflazacort Versus Prednisolone: Randomized Controlled Trial in Treatment of Children With
More informationDEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD]
SCREENING Visit Date: DEMOGRAPHICS / / [YYYY/MM/DD] Consent Signed Date and time / / [YYYY/MM/DD] : Has written assent been obtained? If no, why not? YES NO Gender: Male Female Birthdate: Permission given
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationGENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
More informationSTEROID-RESISTANT NEPHROTIC SYNDROME (SRNS)
MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH CLINICAL RESEARCH CENTRE FOR RARE DISEASES ALDO E CELE DACCO' Villa Camozzi - 24020 Ranica (Bergamo) Italy Telephone 39-35-4535304 fax 39-35-4535373 STEROID-RESISTANT
More informationMinimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong
Minimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong First, it is not uncommon Cameron JS. Am J Kidney Dis 10: 157 171,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationClinicopathologic Characteristics of IgA Nephropathy with Steroid-responsive Nephrotic Syndrome
J Korean Med Sci 2009; 24 (Suppl 1): S44-9 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.S1.S44 Copyright The Korean Academy of Medical Sciences Clinicopathologic Characteristics of IgA Nephropathy with Steroid-responsive
More informationClinical pathological correlations in AKI
Clinical pathological correlations in AKI Dr. Rajasekara chakravarthi Director - Nephrology Star Kidney Center, Star Hospitals Renown clinical services India Introduction AKI is common entity Community
More informationTargeted Adverse Event (ADV)
North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0; 06-20-13 1.
More informationFall 2018 Research Training Program Agenda. S E S SI ON 1, Tuesday, S eptember 11, 2018
S E S SI ON 1, Tuesday, S eptember 11, 2018 7:45 am 8:15 am Sign-In - Refreshments provided, course materials distributed 8 : 1 5 a m - 8 : 2 5 a m Introduction Welcome and overview of the six session
More informationFocal Segmental Glomerulosclerosis and the Nephro6c Syndrome Dr. A. Gangji Dr. P. Marge>s. Part 1: Clinical
Focal Segmental Glomerulosclerosis and the Nephro6c Syndrome Dr. A. Gangji Dr. P. Marge>s Part 1: Clinical Pa#ent DM 18 year old McMaster student Back pain, severe fa#gue Oct 2006 Leg swelling to ER Nov
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 27 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationMr. I.K 58 years old
Mr. I.K 58 years old Hospitalized because of marked pitting peripheral edema (bilateral crural and perimalleolar edema) and uncontrolled blood pressure (BP 150/100 mmhg under treatment). since age 54 years
More informationHIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER
HIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER Gaston Zilleruelo M.D. Professor of Pediatrics Director of Pediatric Nephrology University of Miami/Holtz Children s Hospital Worldwide 33.2 million
More informationC1q nephropathy the Diverse Disease
C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining
More informationNephrotic Syndrome. Department of pediatrics The first affiliated hospital Sun Yat Sen University. Yue Zhihui ( 岳智慧 )
Nephrotic Syndrome Department of pediatrics The first affiliated hospital Sun Yat Sen University Yue Zhihui ( 岳智慧 ) yuezhihui810@yahoo.com.cn Contents Definition Pathophysiology Clinical manifestation
More informationProteinuria. Louisiana State University
Proteinuria W S A V A W C P, 2005 David F. Senior Louisiana State University The normal glomerulus is a highly selective barrier for filtration based on size (and on charge in the case of larger molecules).
More informationActhar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series
Madan et al. BMC Nephrology (2016) 17:37 DOI 10.1186/s12882-016-0241-7 RESEARCH ARTICLE Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series Open Access Arvind Madan
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic kidney disease: early identification and management of adults with chronic kidney disease in primary and secondary
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationTitle: A novel differential diagnostic model based on multiple biological parameters for immunoglobulin A nephropathy
Author's response to reviews Title: A novel differential diagnostic model based on multiple biological parameters for immunoglobulin A nephropathy Authors: Nan Zhen Dong (dongzn@301hospital.com.cn) Yong
More informationClinical trials in childhood steroid sensitive nephrotic syndrome: the PREDNOS studies
Clinical Research Facility Central Manchester University Hospitals NHS Foundation Trust Clinical trials in childhood steroid sensitive nephrotic syndrome: the PREDNOS studies Professor Nick Webb DM FRCP
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
More informationA Randomized Controlled Trial of Intravenous Vs Oral Cyclophosphamide in Steroid Resistant Nephrotic Syndrome
Original article A Randomized Controlled Trial of Intravenous Vs Oral Cyclophosphamide in Steroid Resistant Nephrotic Syndrome Alpana Ohri 1, Kronal Shah 2, Uma Ali 3 1Associate Professor, 2 Jr. Registrar,
More informationOut of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)
Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive
More informationSection 5. Study Procedures
Section 5. Study Procedures 5.1 Visit Locations... 1 5.2 Eligibility Determination SOP... 1 5.3 Screening Visit... 1 5.3.1 Screening and Enrollment Timeframe... 2 5.3.2 Screening Visit Procedures... 2
More informationSAFETY AND EFFICACY ASSESSMENTS
SAFETY AND EFFICACY ASSESSMENTS The observations and procedures described in (Primary Arthritis Assessments) and the Hip or Knee Pain on motion assessment described in (Secondary Arthritis Assessment)
More informationMaolynne Miller Paediatric Nephrologist UHWI Jamaica Kidney Kids Foundation/ International Paediatric Nephrology Association 1st Jamaican Paediatric
Maolynne Miller Paediatric Nephrologist UHWI Jamaica Kidney Kids Foundation/ International Paediatric Nephrology Association 1st Jamaican Paediatric Nephrology Conference October 4 th 2014 Jamaica Conference
More informationDay Care Intravenous Cyclophosphamide Therapy in Steroid Dependent Nephrotic Syndrome
International Journal of advances in health sciences (IJHS) ISSN 2349-7033 Vol2, Issue2, 2015, pp161-166 http://www.ijhsonline.com Research Article Day Care Intravenous Cyclophosphamide Therapy in Steroid
More informationGuidelines for the management of Nephrotic syndrome in children
Guidelines for the management of Nephrotic syndrome in children Children s Kidney Centre University Hospital of Wales Cardiff CF14 4XW DISCLAIMER: These guidelines were produced in good faith by the author(s)
More informationPediatric Nephrology Consult and Referral Guidelines
Pediatric Nephrology Consult and Referral Guidelines Introduction We see children and teens from birth to 21 years. The most common reasons patients are referred to pediatric nephrology services include:
More informationCurrent treatment recommendations in children with IgA nephropathy Selçuk Yüksel
Current treatment recommendations in children with IgA nephropathy Selçuk Yüksel Department of Pediatric Nephrology Pamukkale University School of Medicine IgA Nephropathy The most common cause of primary
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationClinical Commissioning Policy: Rituximab for the treatment of idiopathic membranous nephropathy in adults
Clinical Commissioning Policy: Rituximab for the treatment of idiopathic membranous nephropathy in adults Reference: NHS England: 16047/P NHS England INFORMATION READER BOX Directorate Medical Operations
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationActhar Gel. H. P. Acthar Gel (corticotropin; ACTH) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Acthar Gel Page: 1 of 5 Last Review Date: September 18, 2015 Acthar Gel Description H. P. Acthar
More informationSAE håndtering i protokol CC MM-001
SAE håndtering i protokol CC-92480-MM-001 An SAE is any AE occurring at any dose that: Results in death; Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate risk of
More informationGlomerular diseases mostly presenting with Nephritic syndrome
Glomerular diseases mostly presenting with Nephritic syndrome 1 The Nephritic Syndrome Pathogenesis: proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls escape of RBCs
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationCHAPTER 2 PRIMARY GLOMERULONEPHRITIS
CHAPTER 2 Sunita Bavanandan Lim Soo Kun 19 5th Report of the 2.1: Introduction This chapter covers the main primary glomerulonephritis that were reported to the MRRB from the years 2005-2012. Minimal change
More information